was mainly due to (1) the increase in net construction fees collected from franchisees during the setup phase which itself was related to the opening of new franchise branches and (2) increased rebate

%, mainly are from provision setup for contingent losses of 17.5M THB for noncomplying contract with Public Warehouse Organization (PWO). Unconsolidated financial results of 12-month ended period Unit

accounts. The Company’s Board of Directors has considered and resolved that the price of the investment disposition was appropriate. Summary of SBITO’s financial statements as of September 30, 2017 are as

Thailand Ekachai Medical Care Public Company Limited (the “Company”) would like to clarify on the operating results for the yearly period at the end of 31st December 2018 as follows. Summary The Company

Thailand Ekachai Medical Care Public Company Limited (the “Company”) would like to clarify on the operating results for the yearly period at the end of 31st December 2019 as follows. Summary The Company

Ref U. SET 017/2017 7 August 2017 Subject: Summary of Operating Performance and Financial Status for Quarter 2/2017 To: President The Stock Exchange of Thailand U City Public Company Limited and its

report and consolidated financial statements 2) A summary of the operating results of the listed company and its subsidiaries for the second quarter of the year 2017 (F45-3) Jasmine International Public

of Solvay Biochemicals (Taixing) Limited (“SBT”) amounting to 218 MB. Summary of Performance For Q2 2017, the Company and its subsidiaries recorded net profit of 384 MTHB, increased by 249 MTHB or 5.0

: President of the Stock Exchange of Thailand Enclosures : 1) A copy of financial report and consolidated financial statements 2) A summary of the operating results of the listed company and subsidiaries of the

. * Note Please find further information in the consolidated financial statements. 2 Summary of Performance For Q3 2017, the Company and its subsidiaries recorded net profit of 355 MTHB, increased by 267